This article was originally published in The Gray Sheet
Executive SummaryExpects to begin marketing its Avanti polyurethane condom in the fourth quarter, the company says. The firm, which obtained 510(k) clearance for the device in August 1993 ("The Gray Sheet" Aug. 23, 1993, p. 20), is currently finalizing marketing plans
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.